Shaping and coordinating the implementation science agenda for injectable cabotegravir for PrEP: the role of the Biomedical Prevention Implementation Collaborative (BioPIC)

Shaping and coordinating the implementation science agenda for injectable cabotegravir for PrEP: the role of the Biomedical Prevention Implementation Collaborative (BioPIC)

Abstract Introduction Data from two randomized controlled trials (RCTs) showed that injectable cabotegravir (CAB) for pre‐exposure prophylaxis (PrEP) was efficacious in reducing HIV acquisition. The US Food and Drug Administration approved CAB for PrEP in December 2021; Australia in August 2022; Zim...

ver descrição completa

Detalhes bibliográficos
Principais autores: Mitchell Warren, Wawira Nyagah, Catherine Verde Hashim, Michelle Rodolph, Robin Schaefer, Heather‐Marie A Schmidt, Rachel Baggaley
Formato: Artigo
Idioma:English
Publicado em: Wiley 2023-07-01
coleção:Journal of the International AIDS Society
Assuntos:
cabotegravir
HIV
implementation science
PrEP
prevention
product introduction
Acesso em linha:https://doi.org/10.1002/jia2.26094

Internet

https://doi.org/10.1002/jia2.26094

Registros relacionados